Streptococcus pyogenes in tumor treatment: the past, present and future

Detalhes bibliográficos
Autor(a) principal: Joana Oliveira e Sousa Ferraz Brandão
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/128759
Resumo: In light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn.
id RCAP_15f0ad2acc332a638571c80488ffca66
oai_identifier_str oai:repositorio-aberto.up.pt:10216/128759
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Streptococcus pyogenes in tumor treatment: the past, present and futureMedicina clínicaClinical medicineIn light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn.2020-06-092020-06-09T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/128759TID:202613950engJoana Oliveira e Sousa Ferraz Brandãoinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:33:06Zoai:repositorio-aberto.up.pt:10216/128759Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:26:23.905958Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Streptococcus pyogenes in tumor treatment: the past, present and future
title Streptococcus pyogenes in tumor treatment: the past, present and future
spellingShingle Streptococcus pyogenes in tumor treatment: the past, present and future
Joana Oliveira e Sousa Ferraz Brandão
Medicina clínica
Clinical medicine
title_short Streptococcus pyogenes in tumor treatment: the past, present and future
title_full Streptococcus pyogenes in tumor treatment: the past, present and future
title_fullStr Streptococcus pyogenes in tumor treatment: the past, present and future
title_full_unstemmed Streptococcus pyogenes in tumor treatment: the past, present and future
title_sort Streptococcus pyogenes in tumor treatment: the past, present and future
author Joana Oliveira e Sousa Ferraz Brandão
author_facet Joana Oliveira e Sousa Ferraz Brandão
author_role author
dc.contributor.author.fl_str_mv Joana Oliveira e Sousa Ferraz Brandão
dc.subject.por.fl_str_mv Medicina clínica
Clinical medicine
topic Medicina clínica
Clinical medicine
description In light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-09
2020-06-09T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/128759
TID:202613950
url https://hdl.handle.net/10216/128759
identifier_str_mv TID:202613950
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136177289166848